Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes

Clinical Cardiology

Volumn 32, Issue 9, 2009, Pages

  Yan, Zhenxian ^a   Zhou, Yujie ^a   Zhao, Yingxin ^a   Li, Yueping ^a   Nie, Xiaomin ^a   Zhou, Zhiming ^a   Jia, Dean ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN; PLACEBO; TIROFIBAN; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FUNCTIONAL STATUS; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; TYROSINE;

EID: 70349084596     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20475     Document Type: Article

References (18)

1. Hartman GD. Tirofiban hydrochloride: platelet antiaggregatory GP IIb/IIIa receptor antagonist. Drugs Future. 1995;20:897-901.
2. Madan M, Berkawitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998;98:2629-2635.
3. Lynch JJ, Cook JJ, Sitko GR, et al.Nonpeptide glycoprotein IIb/IIIa inhibitors. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther. 1995;272:20-32.
4. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
5. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497. (Pubitemid 28226276)
6. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96(5):1445-1453. (Pubitemid 27375335)
7. Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty. Cardiology. 2004;102:18-23. (Pubitemid 38490256)
8. Zhang Q, Zhang RY, Zhang JS, et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl). 2006;119:165-168. (Pubitemid 43796935)
9. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
10. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: will they be useful when given chronically? Circulation. 1996;94:866-868.
11. Danzi GB, Capuano C, Migliorini A, Sesana M, Baglini R, Antoniucci D. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr Med Opin. 2003;19:28-33. (Pubitemid 36378317)
12. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial. JAMA. 2005;293:2109-2117. (Pubitemid 40617063)
13. Teirstein PS, Kao J, Watkins M, et al. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol. 2005;96(4):500-505. (Pubitemid 41135874)
14. Braunwald E, Antman E, Beasley J, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2000;36(3):970-1062. (Pubitemid 30149196)
15. De Queiroz Fernandes Arau JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta analysis of randomized, controlled trials. Am Heart J. 2004;148:937-943.
16. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362-366. (Pubitemid 38944261)
17. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-e304.
18. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007; 28:1598-1660.